EXEL discovers, develops, and commercializes new treatments to battle hard-to-treat cancers. Its product portfolio continues to expand, focusing on more types of tumors, with EXEL treatments proving to be leaders against renal cell carcinoma. The company’s expanding treatment portfolio and ambitious growth plans position it for further expansion.

EXEL’s fourth-quarter results for fiscal 2024 showed roughly $567 million in quarterly revenue and almost $140 million in GAAP net income. The company also has almost $2 billion in cash and marketable securities on hand to fund future growth plans, part of which include more share repurchases on top of the almost $656 million bought in 2024. Also, the company is bolstering its oncology pipeline, eyeing revenue of $3 billion for its cabo treatment by 2030 and $5 billion for its zanza treatment by 2033.

It’s no wonder EXEL shares are up almost 57% in a year – and they could rise more. MAPsignals data shows how Big Money investors are betting heavily on the forward picture of the stock.

Big Money Lifts Exelixis

Institutional volumes reveal plenty. Recently, EXEL has enjoyed strong investor demand, which we believe to be institutional support.

Each green bar signals unusually large volumes in EXEL shares. They reflect our proprietary inflow signal, pushing the stock higher:

Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with Exelixis.

Exelixis Fundamental Analysis

Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, EXEL has had strong sales and earnings growth:

• 3-year sales growth rate (+14.8%)
• 3-year earnings growth rate (+55.9%)

Source: FactSet

Also, EPS is estimated to ramp higher this year by +16.4%.

Now it makes sense why the stock has been powering to new heights. EXEL has a track record of strong financial performance.

Marrying great fundamentals with our proprietary software has found some big winning stocks over the long term.

Exelixis has been a top-rated stock at MAPsignals for years. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

It’s made the rare Top 20 report multiple times in the last year. The blue bars below show when EXEL was a top pick…lifting with time:

Tracking unusual volumes reveals the power of money flows.

This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.

Exelixis Price Prediction

The EXEL rally isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no position in EXEL at the time of publication.

If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level, learn more about the MAPsignals process here.

This article was originally posted on FX Empire

More From FXEMPIRE:

• Earnings, Policy Growth Keep Progressive Gaining
• Germany’s Election: Reform Momentum Strengthens, but Debt Brake Reform Challenging
• Veeva Shares Advance on Revenue, AI Growth
• Exelixis Growth Continues with Big Money Boosts
• CME Group Rising on Record Revenue
• Monster’s Comeback Story Fueled by Big Money